SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Collaboration
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century
Bristol Myers Squibb aims to generate around $1.5 billion in savings through 2025—a goal that it hopes to reach by lowering third-party expenditures, focusing only on key growth brands and cutting some 2,200 jobs by year-end.
December 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of businessman reflecting himself in the mirror, loop surreal concept facing to 2023 ahead.
Duchenne Muscular Dystrophy
Déjà Vu for PepGen as FDA Places Hold on DMD Drug
The FDA has put a stop to U.S. initiation of PepGen’s Phase II trial for its Duchene muscular dystrophy treatment. The company faced the same hurdle for an earlier neuromuscular candidiate in 2023.
December 16, 2024
 · 
2 min read
 · 
Annalee Armstrong
Sep 17, 2020 Fremont / CA / USA - Novo Nordisk headquarters in Silicon Valley; Novo Nordisk A/S is a Danish multinational pharmaceutical company
Manufacturing
Novo Deepens Denmark Commitment With $1.2B Rare Disease Production Facility
Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which analysts expect will help the pharma expand its production capacity.
December 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Update: AbbVie headquarters building in California
Mergers & acquisitions
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq, according to Guggenheim Partners analysts.
December 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration
Mergers & acquisitions
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
December 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .
Neuroscience
5 Clinical Assets That Flopped in 2024
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five clinical trial flops that stole headlines over the past 12 months.
December 16, 2024
 · 
6 min read
 · 
Heather McKenzie
Craftsmen are using silicone adhesives for general and industrial applications.
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
 · 
6 min read
 · 
Kate Goodwin
3d illustration showing amyloid plaques in Alzheimer's disease
Alzheimer’s disease
Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of these anti-amyloid antibodies and the amyloid hypothesis overall.
December 16, 2024
 · 
6 min read
 · 
Heather McKenzie
Get a good deal, partnership concept. Contemporary art collage, modern design. Handshake of two businessmen. Surrealistic conceptual poster.
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
 · 
1 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS